Zhang Lin, Kim Sungjune, Ren Xiubao
Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
National Clinical Research Center of Cancer, Tianjin, China.
Front Oncol. 2020 Sep 8;10:1721. doi: 10.3389/fonc.2020.01721. eCollection 2020.
Sirtuin 2 (SIRT2) is a member of the sirtuin protein family. It is a Class III histone deacetylase (HDACs) and predominantly localized to the cytosol. SIRT2 deacetylates histones and a number of non-histone proteins and plays a pivotal role in various physiologic processes. Previously, SIRT2 has been considered indispensable during carcinogenesis; however, there is now a significant controversy regarding whether SIRT2 is an oncogene or a tumor suppressor. The purpose of this review is to summarize the physiological functions of SIRT2 and its mechanisms in cancer. We will focus on five malignancies (breast cancer, non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, and glioma) to describe the current status of SIRT2 research and discuss the clinical evaluation of SIRT2 expression and the use of SIRT2 inhibitors.
沉默调节蛋白2（SIRT2）是沉默调节蛋白家族的成员。它是一种III类组蛋白去乙酰化酶（HDACs），主要定位于细胞质中。SIRT2使组蛋白和许多非组蛋白去乙酰化，并在各种生理过程中发挥关键作用。以前，SIRT2在致癌过程中被认为是不可或缺的；然而，现在关于SIRT2是癌基因还是肿瘤抑制因子存在重大争议。本综述的目的是总结SIRT2的生理功能及其在癌症中的机制。我们将重点关注五种恶性肿瘤（乳腺癌、非小细胞肺癌、肝细胞癌、结直肠癌和神经胶质瘤），以描述SIRT2的研究现状，并讨论SIRT2表达的临床评估以及SIRT2抑制剂的应用。
